NTRK2 and Alzheimer disease: In particular, LM22A4, the small molecule TrkB agonist with neuroprotective efficacy in preclinical models of neurodegeneration, also induced AMPA receptor trafficking alongside promoting increased synaptic incorporation of AMPA receptor through the increase in AMPA receptor trafficking, which also improved spatial memory performance in models of AD treated at the same time as LM22A4 [279].